Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Several routes of administration can be used to deliver mesenchymal stem cells (MSCs) to the brain. In the present study, MSCs were delivered throughout the neuraxis and brain via intra-spinal cavity injection. MSCs were injected into the spinal cavities of rats, and stem cell migration was tracked and quantified.

Abstract

Mesenchymal stem cells (MSCs) have been studied for the treatment of various diseases. In neurodegenerative diseases involving defects in both the brain and the spinal cord, the route of administration is very important, because MSCs must migrate to both the brain and the spinal cord. This paper describes a method for administering MSCs into the spinal canal (intraspinal cavity injection) that can target the brain and spinal cord in a rat model. One million MSCs were injected into the spinal canals of rats at the level of lumbar vertebrae 2-3. After administration, the rats were euthanized at 0, 6, and 12 h post-injection. Optical imaging and quantitative real-time polymerase chain reaction (qPCR) were used to track the injected MSCs. The results of the present study demonstrated that MSCs administered via the spinal cavity could be detected subsequently in both the brain and spinal cord at 12 h. Intraspinal cavity injection has the advantage of not requiring general anesthesia and has few side effects. However, the drawback of the low migration rate of MSCs to the brain must be overcome.

Introduction

Mesenchymal stem cells
Under disease conditions, MSCs secrete disease-specific therapeutic substances via paracrine actions1 that have been reported to regulate immune responses, restore damaged tissues, and remove toxic substances2. Therefore, MSC therapy is considered more effective than single-target therapy in treating multifactorial diseases such as Alzheimer's disease and sarcopenia3,4,5,6. Additionally, in contrast to pharmaceuticals, MSCs have a homing effect,....

Protocol

NOTE: This study was approved by the Institutional Animal Care and Use Committee (Approval number: 20170125001, Date: January 25, 2017) of the Samsung Biomedical Research Institute (SBRI) at Samsung Medical Center. As an accredited facility of the Association for Assessment and Accreditation of Laboratory Animal Care International, the SBRI acts in accordance with the guidelines set forth by the Institute of Laboratory Animal Resources.

1. Preparation of human Wharton's jelly-derived MSCs

Representative Results

To evaluate the efficacy of intraspinal cavity injection of MSCs, DiD-labeled MSCs were used in the present study. Before injecting MSCs into the spinal cavity, the labeling efficacy was assessed in vitro using optical imaging and fluorescence microscopy (Figure 1). After staining the MSCs with the DiD labeling reagent using the procedure described in protocol section 3.1, optical images were taken of the culture plates on which DiD-labeled MSCs were seeded (Figure 1A

Discussion

The optimal route of administration for treatment with MSCs should be chosen depending on the target disease, the patient's condition, and the type of drug to be delivered. In cell therapies, including MSC therapy, direct injection of stem cells into the brain or intrathecally via the CSF must be considered as the cells cannot pass through the BBB19. Intraspinal cavity injection is relatively non-invasive and does not cause neuronal damage in the brain, unlike intracerebroventricular injection.......

Acknowledgements

This study was supported by grants from the Basic Research Program through the National Research Foundation of South Korea (NRF), funded by the Ministry of Education (NRF-2017R1D1A1B03035940), and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant numbers: HI14C3484 and HI18C0560). We would like to thank Editage (www.editage.co.kr) for English language editing.

....

Materials

NameCompanyCatalog NumberComments
0.25% Trypsin-EDTAGibco-invitrogen25200114Cell culture
Fetal bovine serumbiowestS1520Culture medium supplement
gentamicinGibco-invitrogen15710-072Culture medium supplement
Gentra Puregene Tissue KitQIAGEN158689gDNA isolation
MEM, no glutamine, no phenol redGibco51200038WJ-MSC fomulation for injection
Miminum Essential Medium alphaGibco-invitrogen12571063WJ-MSC culture medium
Power SYBR Green PCR Master MixApplied Biosystems4368577quantitative real time PCR reagent
QuantStudio 6 Flex Real-Time PCR SystemThermo fisher4485694quantitative real time PCR
trypan blueGibco15250061Injection
Vybrant DiD Cell-Labeling SolutioninvitrogenV22887Stem cell labeling solution
Xenogen IVIS Spectrum systemPerkin Elmer124262Optical imaging device

References

  1. Gnecchi, M., Danieli, P., Malpasso, G., Ciuffreda, M. C. Paracrine mechanisms of mesenchymal stem cells in tissue repair. Methods in Molecular Biology. 1416, 123-146 (2016).
  2. Liang, X., Ding, Y., Zhang, Y., Tse, H. F., Lian, Q.

Explore More Articles

Mesenchymal Stem CellsIntraspinal Cavity InjectionSpinal CordBrainMigrationOptical ImagingQPCRNeurodegenerative Diseases

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved